Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 977 02 0?
Displaying drugs 676 - 700 of 1414 in total
CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are then able to differentiate into bone, cartilage, and adipose tissue. The MCA-derived MSCs can be obtained from induced pluripotent...
Investigational
The IN01 Vaccine, sponsored by the Instituto Oncologico Dr Rosell, IN3BIO, and PANGAEA, is a compound containing recombinant bacteria . These cultures contain EGF-4-EGF with the cholera toxin B-subunit domain G33D sequence . Administration of the vaccine stimulates the production of anti-epidermal growth factor (anti-EGF) neutralizing antibodies . Of note,...
Investigational
STG-001 is under investigation in clinical trial NCT04489511 (Study of STG-001 in Subjects With Stargardt Disease).
Investigational
MGD-024 is an anti-CD123/anti-CD3 bispecific DART molecule.
Investigational
ENB-003 is a selective and potent inhibitor of the endothelin B receptor (ETBR) being investigated for cancer.
Investigational
MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
Investigational
KF-0210 is a small molecule developed by Keythera Pharmaceuticals. It is being investigated for cancers.
Investigational
Investigational
Investigational
AMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.
Investigational
Investigational
Investigational
BBT-059 is a long-acting interleukin-11 analog.
Investigational
Investigational
TLY-012 is a PEGylated recombinant human tumor necrosis factor-related apoptosis-inducing ligand (PEGylated TRAIL).
Investigational
TRK-001 is an autologous regulatory T-cell therapy. It is being investigated for the prevention of graft rejection following solid organ transplantation.
Investigational
PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Investigational
BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.
Investigational
APL-030 is a orally-active small molecule inhibitor of GCN2.
Investigational
ABG-023 is a glucagon analog which is soluble and solution-stable.
Investigational
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
AZD0424 has been used in trials studying the treatment of Advanced Solid Tumours.
Investigational
GDC-0927 is under investigation in clinical trial NCT02316509 (A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer).
Investigational
VM4-037 is under investigation in clinical trial NCT00884520 (An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037).
Investigational
SOBI-003 is a chemically modified variant of a recombinant human sulfamidase. It is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).
Investigational
Displaying drugs 676 - 700 of 1414 in total